Researchers and engineers at Mersana develop novel drug conjugates that maximize the potential of new and established therapeutic classes. The company’s technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications.

Utilizing the company’s proprietary technology, researchers we are developing a portfolio of next-generation antibody-drug conjugates (ADC) with superior properties not found with current ADC technologies. The clinical pipeline consists of two cancer therapeutics with blockbuster potential. XMT-1001 is a potentially best-in-class novel “tecan” conjugate that is currently being investigated in a Phase Ib extension trial in patients with lung cancers. XMT-1107 is a first-in-class anti-angiogenic conjugate with a unique mechanism of action that has completed a Phase I trial in patients with refractory, advanced solid tumors. XMT-1107 was licensed to Teva on a worldwide basis except for Japan, where Mersana elected to retain rights.

These clinical candidates reflect the successful application of our unique conjugation system. This versatile conjugation system integrates Fleximer?, a clinically validated biodegradable polymer, with a broad array of customized linker chemistries designed to control conjugation, stability and release of diverse classes of therapeutic payloads. This system provides important benefits required for the development of next-generation drugs across therapeutic modalities, including ADCs, antibody fragments, small molecules and biologics, as well as synergistic drug combinations.

840 Memorial Drive
Cambridge, MA 02139

Web: Mersana Therapeutics, Inc.

Advertisement #3

Advertisement #5
Previous articleMerrimack
Next articleMoradec
Sonia Portillo
Sonia Portillo is an associate editor of ADC Review | Journal of Antibody-Drug Conjugates, an online, peer reviewed publication dedicated to following the developments of ADCs and other targeted therapies and a contributing editor to Onco'Zine. Portillo studies cancer treatment from a pharmacological perspective, specifically in the area of precision and personalized medicine.